2 completed, 1 active not recruiting, 1 unknown. 4 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 2, Active not recruiting 1, Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Systemic Inflammation: new trials by email Literature Review of Systemic Inflammation trials Research Report on Systemic Inflammation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation Ziltivekimab, Placebo - Heart Failure, Systemic Inflammation | Phase 3 | Active not recruiting | Novo Nordisk A/S | 673 | 2024-04-01 | 2026-10-01 |
| Preventing Systemic Inflammation After Cardiac Surgery With Alkaline Phosphatase RESCAP®, placebo - Systemic Inflammation, Cardiopulmonary-bypass | Phase 2 / Phase 3 | Unknown | Alloksys Life Sciences B.V. | 1250 | 2017-11-01 | 2024-04-19 |
| Oritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I) Single-Dose IV Oritavancin Diphosphate, IV Vancomycin, Placebo - Wound Infection, Abscess | Phase 3 | Completed | Melinta Therapeutics, Inc. | 968 | 2010-12-01 | 2022-08-01 |
| Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection Single-Dose IV Oritavancin Diphosphate, IV Vancomycin - Wound Infection, Abscess | Phase 3 | Completed | Melinta Therapeutics, Inc. | 1019 | 2010-12-01 | 2021-05-05 |
Abscess (2) · Cellulitis (2) · Wound Infection (2) · Heart Failure (1)
Connective Tissue Diseases (2) · Infections (2) · Inflammation (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Skin Diseases, Infectious (2) · Skin and Connective Tissue Diseases (2) · Suppuration (2) · Cardiovascular Diseases (1) · Heart Diseases (1)
Vancomycin (2) · ziltivekimab (1)
Melinta Therapeutics, Inc. (2) · Alloksys Life Sciences B.V. (1) · Novo Nordisk A/S (1)
United States (3) · Australia (2) · Germany (2) · Malaysia (2) · Portugal (2) · Spain (2) · Argentina (1) · Austria (1) · Belgium (1) · Bulgaria (1) · Canada (1) · Czechia (1) · France (1) · Greece (1) · India (1)
G. Ralph Corey, MD (2) · Dominik Wiedemann, Prof.Dr. (1)
PMID 27370913, PMID 29358292, PMID 24897083, PMID 25294250
2023 (1)